Natsimbio holding (part of the Rostec State Corporation) has been appointed the sole contractor for processing blood plasma for the needs of the FMBA of Russia and the production of immunoglobulins, including human normal immunoglobulin and human immunoglobulin against coronavirus infection, Vademecum reports.
The Government of the Russian Federation issued a corresponding order on January 29. Natsimbio will retain the status of the sole supplier until the end of 2023.
In turn, the company will be able to order services from subcontractors, but it must perform at least 2% of the work under government contracts using its own resources.
Natsimbio will be the contractor for human normal immunoglobulin, albumin, human immunoglobulin against COVID-19, immunoglobulin against tick-borne encephalitis, human tetanus immunoglobulin, human antistaphylococcal immunoglobulin, and human immunoglobulin against hepatitis B,” the publication specfies.
The Ministry of Industry and Trade has previously warned about the risk of immunoglobulin shortage in the Russian Federation due to the low maximum selling price for the drug that had been established.
As it became known earlier, Natsimbio supplied almost 100 million doses of vaccines against dangerous infections in 2021.